Conjugates of Biologically Active Molecules to Functionalized Polymers
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 14/407,580, filed Dec 12, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,383,946 | Conjugates of Biologically Active Molecules to Functionalized Polymers In force · High confidence | Quiapeg Pharmaceuticals AB | In force | High confidence | ||
| US 11,510,989 | Conjugates of Biologically Active Molecules to Functionalized Polymers In force · High confidence | Quiapeg Pharmaceuticals AB | In force | High confidence | ||
| US 10,806,796 | Conjugates of Biologically Active Molecules to Functionalized Polymers Lapsed Oct 20, 2024 on the fee record High confidence | Quiapeg Pharmaceuticals AB | Lapsed Oct 20, 2024 on the fee record | High confidence | ||
| US 10,010,621 | Conjugates of Biologically Active Molecules to Functionalized Polymers Lapsed Jul 3, 2026 on the fee record High confidence | Quiapeg Pharmaceuticals AB | Lapsed Jul 3, 2026 on the fee record | High confidence | ||
| Application 17/974,258 | Conjugates of Biologically Active Molecules to Functionalized Polymers Abandoned Abandoned Dec 1, 2023 | Quiapeg Pharmaceuticals AB | Abandoned | Abandoned Dec 1, 2023 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Quiapeg Pharmaceuticals AB.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.